Inflammation induced by lipid mediators and protein from transfusion products

IF 6.6 2区医学 Q1 IMMUNOLOGY

Current Opinion in Immunology Pub Date : 2025-07-03 DOI:10.1016/j.coi.2025.102605

Chloe Heranney , Mailys Portier , Fabrice Cognasse , Duchez Anne-Claire

{"title":"Inflammation induced by lipid mediators and protein from transfusion products","authors":"Chloe Heranney , Mailys Portier , Fabrice Cognasse , Duchez Anne-Claire","doi":"10.1016/j.coi.2025.102605","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose of the review</h3><div>Platelet and red blood cell (RBC) transfusions, whether used as prophylactic measures or therapeutic interventions, are critical for saving lives. However, the composition of platelet and RBC concentrates used for transfusion may contribute to adverse reactions following transfusion.</div></div><div><h3>Recent finding</h3><div>Recent studies on platelet and RBC concentrates have focused on their composition, including lipid mediators and proteins such as cytokines and chemokines, and their potential role in transfusion-related adverse reactions. This review aims to synthesize both recent and earlier findings, offering an overview of the involvement of these bioactive molecules in transfusion reactions.</div></div><div><h3>Summary</h3><div>Lipid mediators and proteins could serve as predictive biomarkers for adverse reactions to specific transfusions. The integration of personalized medicine/transfusion should be explored to optimize transfusion practices and improve patient outcomes.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"95 ","pages":"Article 102605"},"PeriodicalIF":6.6000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952791525000810","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of the review

Platelet and red blood cell (RBC) transfusions, whether used as prophylactic measures or therapeutic interventions, are critical for saving lives. However, the composition of platelet and RBC concentrates used for transfusion may contribute to adverse reactions following transfusion.

Recent finding

Recent studies on platelet and RBC concentrates have focused on their composition, including lipid mediators and proteins such as cytokines and chemokines, and their potential role in transfusion-related adverse reactions. This review aims to synthesize both recent and earlier findings, offering an overview of the involvement of these bioactive molecules in transfusion reactions.

Summary

Lipid mediators and proteins could serve as predictive biomarkers for adverse reactions to specific transfusions. The integration of personalized medicine/transfusion should be explored to optimize transfusion practices and improve patient outcomes.

查看原文本刊更多论文

由输注产品的脂质介质和蛋白质引起的炎症

综述的目的血小板和红细胞（RBC）输注，无论是作为预防措施还是治疗干预措施，都对挽救生命至关重要。然而，用于输血的血小板和红细胞浓缩物的组成可能导致输血后的不良反应。最近对血小板和红细胞浓缩物的研究主要集中在它们的组成，包括脂质介质和蛋白质，如细胞因子和趋化因子，以及它们在输血相关不良反应中的潜在作用。这篇综述旨在综合最近和早期的发现，提供这些生物活性分子参与输血反应的概述。脂质介质和蛋白可作为特异性输血不良反应的预测性生物标志物。应探索个性化医疗/输血的整合，以优化输血实践，改善患者预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Immunology 医学-免疫学

CiteScore

13.30

自引率

1.40%

发文量

审稿时长

67 days

期刊介绍： Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed. In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications. Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students. Current Opinion in Immunology builds on Elsevier''s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists'' workflow.